Acura Pharmaceuticals ( (ACUR) ) has released a notification of late filing.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Acura Pharmaceuticals has filed a Form 12b-25, indicating a delay in submitting its Form 10-Q (Quarter Report) for the financial period ending June 30, 2025. The primary reason for the delay is the company’s liquidity issues, which have affected its ability to meet daily operational obligations. Acura Pharmaceuticals is actively seeking funding solutions and is dependent on loans from Abuse Deterrent Pharma, LLC to sustain operations, although there is no assurance these loans will continue or be sufficient for long-term needs. The company anticipates filing the delayed report within five calendar days following the due date. There are no expected significant changes in financial results from the previous fiscal year, and the company has not filed several other quarterly and annual reports from previous years. Acura Pharmaceuticals continues to work on compliance efforts, with the notification signed by Robert A. Seiser, SVP & CFO.
More about Acura Pharmaceuticals
Average Trading Volume: 1,000
Technical Sentiment Signal: Sell
Current Market Cap: $330K
For an in-depth examination of ACUR stock, go to TipRanks’ Overview page.